Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Behçet disease
- 31 Downloads
We evaluated ocular symptoms and activity of retinal vasculitis of Behçet disease before and after infliximab therapy, using Behçet disease ocular attack score 24 (BOS24) and fluorescein angiography (FA) score. We also analyzed the efficacy of infliximab for ocular and extraocular symptoms.
Subject and methods
Using medical records, we analyzed FA and BOS24 to evaluate the association between the efficacy of infliximab therapy and FA as well as BOS24 scores. Further, we evaluated the association between FA scores and extraocular symptoms.
After 2 years of infliximab therapy, 6-month BOS24 was significantly reduced compared to that before treatment (PreBOS24-6M). After 4 years of infliximab therapy, 6-month BOS24 was also significantly reduced compared to preBOS24-6M. After 2 years of infliximab therapy, FA score median (interquartile range) decreased significantly compared to that before treatment [FA-2Y vs. preFA: 0 (0-0) vs.15.5 (12-24); P < 0.0001; n = 38]. The FA-4Y score in subjects followed for at least 4 years was also significantly lower than the preFA score [0 (0-0) vs.16.5 (12-24.5); P < 0.0001; n = 28]. Among 38 patients, extraocular symptoms were resolved following treatment in 29 cases (76.3%). No significant correlation was observed between the improvement in FA-2Y and FA-4Y scores and the occurrence and persistence of extraocular symptoms (P = 0.33; n = 38 or P = 0.4; n = 28).
Infliximab therapy is effective for the treatment of ocular and extraocular involvement of Behçet disease. BOS24 and FA scores are useful for evaluating the efficacy of infliximab therapy.
KeywordsBehçet disease BOS24 FA score Ocular symptoms Extraocular symptoms
- DAS 28
Disease activity score in rheumatoid arthritis
Behçet disease ocular attack score 24
We thank Ms. Teresa Nakatani for critical revision of the manuscript.
This research is supported by the Ministry of Health and Labour Sciences Research Grants of Japan for Research on Rare and Intractable Diseases.
Conflicts of interest
A. Umazume, None; T. Kezuka, Grant (Mitsubishi Tanabe Pharma), Lecture fee (Mitsubishi Tanabe Pharma); Y. Usui, None; J. Suzuki, None; H. Goto, Grant (Mitsubishi Tanabe Pharma), Lecture fee (Mitsubishi Tanabe Pharma).
- 4.Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(786–96):e3.Google Scholar
- 7.Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab. Graefes Arch Clin Exp Ophthalmol. 2012;250:1081–7.CrossRefPubMedGoogle Scholar
- 8.Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheumatol. 1995;38:44–8.CrossRefGoogle Scholar
- 14.No author listed. Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet. 1990;335:1078–80.Google Scholar
- 22.Spitznas M. Understanding Fluorescein Angiography. Berlin: Springer; 2006. p. 73–99.Google Scholar
- 23.Nussenblatt R. Uveitis: Fundamentals and Clinical Practice. 4th ed. Philadelphia: Elsevier; 2010. p. 42–71.Google Scholar
- 27.van der Maas A, Kievit W, van den Bemt BJ, van den Hoogen FH, van Riel PL, den Broeder AA. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012;71:1849–54.CrossRefPubMedGoogle Scholar